# Cerity Partners Ventures

> Cerity Partners Ventures is a VC fund backing Software. See 79 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Haddonfield, United States
- Total investments: 79
- Last investment: Jul 2025
- Lead investor: 1%
- Fund size: $100M
- Last fund: Nov 2020
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/touchdown-ventures
- X (Twitter): https://twitter.com/touchdown_vc
- Website: http://www.touchdownvc.com

Cerity Partners Ventures is a corporate venture capital (CVC) firm that partners with corporations to invest in early and growth-stage companies across a variety of industries, including information technology, media, consumer, health, and industrial.

## Contacts

5 contacts available for Cerity Partners Ventures. Shizune tracks 17 team members at Cerity Partners Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/touchdown-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1M–$14M |
| Series A | $4M–$25M |
| Series B | $15M–$44M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 15 | 19% |
| Artificial Intelligence | 10 | 13% |
| Health Care | 9 | 11% |
| Machine Learning | 8 | 10% |
| SaaS | 7 | 9% |

157 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 19 | 24% |
| Series B | 18 | 23% |
| Seed | 16 | 20% |
| Series C | 9 | 11% |
| Funding Round | 6 | 8% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 62 | 78% |
| Israel | 4 | 5% |
| Canada | 2 | 3% |
| India | 1 | 1% |
| Australia | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Allison Goldberg | Venture Partner | 9 | https://shizune.co/investors/profile/allison-goldberg |
| Austin Chung | Analyst | 0 | https://shizune.co/investors/profile/austin-chung |
| Daniel Deeney | Venture Partner | 2 | https://shizune.co/investors/profile/daniel-deeney |
| David Horowitz | Founder and CEO | 14 | https://shizune.co/investors/profile/david-b-horowitz |
| Deborah Zajac | Director | 0 | https://shizune.co/investors/profile/deborah-zajac |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Syntis Bio | Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. | $33M | Series A | Jul 01, 2025 |  |
| AmpUp | AmpUp is an electric vehicle charging company that enables drivers, hosts, and fleets to charge stress-free. | $15M | Series A | Sep 26, 2024 |  |
| Atropos Health | Atropos Health rapidly provides personalized real-world evidence for any clinical decision | $33M | Series B | May 23, 2024 |  |
| Trust & Will | Trust & Will is an online service providing legal forms and information that makes creating estate planning easy, fast, and secure. It is not a law firm and is not a substitute for a lawyer’s advice about complex estate planning. The company is backed by some venture capital firms including Revolution’s Rise of the Rest, Western TechnologyInvestments, Luma Launch, Halogen Ventures, and Techstars, as well as angel investors.Trust & Will was founded in 2017 and is headquartered in San Diego, CA. |  | Venture - Series Unknown | Jan 18, 2024 |  |
| Valid8 Financial | Valid8 Financial offers financial services investigations by extracting and reconciling banking transactions from any PDF statement. The company was founded in 2017 by Tod McDonald and Chris McCall and is headquartered in Seattle, Washington. | $8.5M | Series A | Nov 30, 2023 |  |
| DetraPel | DetraPel is a cleantech Advanced Materials company specializing in synthesizing & manufacturing PFAS-Free Protective Coatings. | $7.6M | Series A | Sep 11, 2023 |  |
| MEND | MEND is a life sciences company with a mission to help people heal and live their healthiest. The company is currently researching and developing targeted clinical nutrition and medical food interventions to enhance patient outcomes, from injury and surgery to aging and physical performance. MEND has been adopted by numerous hospitals, healthsystems, professional sports teams across all major leagues, and the elite forces of the US Military. The company is headquartered in New York City. | $16.5M | Series A | Jun 06, 2023 |  |
| Steno | Steno provides litigation support by connecting legal teams with court reporters, remote deposition tools, and transcript management. The company facilitates in-person and virtual depositions by offering scheduling, videography, and real-time reporting capabilities. Its platform integrates digital tools that allow attorneys to manage casematerials, review transcripts, and coordinate proceedings within a unified system.Steno also supports legal workflows through automated transcript processing and secure document handling, helping law firms organize and access deposition records efficiently. The company works with certified court reporters and legal professionals to ensure accurate documentation of legal proceedings. | $15M | Series B | May 23, 2023 |  |
| Syntis Bio | Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. | $15.4M | Seed | Jan 17, 2023 |  |
| Novome Biotechnologies | Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications. | $43.5M | Series B | Sep 13, 2022 |  |

10 of 79 investments shown.

## Co-investors
- [Eighteen94 Capital](https://shizune.co/investors/profile/eighteen94-capital) — VC Fund, 6 deals together
- [Allegion Ventures](https://shizune.co/investors/profile/allegion-ventures) — VC Fund, 5 deals together
- [Accomplice](https://shizune.co/investors/profile/accomplice-atlas-venture) — VC Fund, 4 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 4 deals together
- [S2G Investments](https://shizune.co/investors/profile/s2g-ventures) — VC Fund, 4 deals together
- [Colorcon Ventures](https://shizune.co/investors/profile/colorcon-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund
- [The LegalTech Fund](https://shizune.co/investors/profile/the-legaltech-fund) — VC Fund
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Legal Investors](https://shizune.co/investors/legal-investors)
- [Legal VC Funds](https://shizune.co/investors/legal-vc-funds)
- [Legal VC Funds in United States](https://shizune.co/investors/legal-vc-funds-united-states)
- [Climate VC Funds in Australia](https://shizune.co/investors/climate-vc-funds-australia)
- [Sustainability VC Funds in Australia](https://shizune.co/investors/sustainability-vc-funds-australia)
- [Impact VC Funds in Australia](https://shizune.co/investors/impact-vc-funds-australia)

## FAQ

### What does Cerity Partners Ventures invest in?

Cerity Partners Ventures invests primarily in Software, Artificial Intelligence and Health Care startups, most often at Series A and Series B stage. Most of the 79 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Cerity Partners Ventures's check size?

Cerity Partners Ventures typically joins rounds of $1M–$14M at Seed, $4M–$25M at Series A and $15M–$44M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cerity Partners Ventures participates in.

### How do I contact Cerity Partners Ventures?

Public channels for Cerity Partners Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cerity Partners Ventures?

The team at Cerity Partners Ventures includes Allison Goldberg (Venture Partner), Austin Chung (Analyst) and Daniel Deeney (Venture Partner), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co